DOD Biotech PCL (DOD.BK) Azione Prezzo
DOD Biotech PCL Prezzo
Il fatturato è cresciuto a un tasso composto del 60,6% annuo negli ultimi 12 anni, raggiungendo 608,98 Mio. THB. L'utile per azione è cresciuto del 2,3% all'anno negli ultimi 10 anni. Il margine netto di DOD Biotech PCL si attesta al 9,8%, in calo rispetto al 23,0% di alcuni anni fa. DOD Biotech PCL offre attualmente un rendimento da dividendo di circa il 6,25%. Il payout ratio è pari a circa il 15% degli utili. Il dividendo è cresciuto del 243,4% all'anno negli ultimi 2 anni.
DOD Biotech PCL Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
DOD Biotech PCL Azione e analisi azionaria
Domande frequenti sull'azione DOD Biotech PCL
The business model of DOD Biotech PCL focuses on the biotechnology industry. DOD Biotech PCL is a company that specializes in research and development, manufacturing, and distribution of biotech products. They aim to provide innovative solutions and advancements in areas including healthcare, agriculture, and environmental sciences. With a strong commitment to scientific excellence, DOD Biotech PCL leverages cutting-edge technologies to develop and produce a wide range of biotech products and services. By constantly investing in research and maintaining strategic partnerships, DOD Biotech PCL strives to shape the future of biotechnology and make substantial contributions to various sectors of the economy.
DOD Biotech PCL is primarily active in the biotechnology industry.
The main competitors of DOD Biotech PCL in the market include companies such as XYZ Biotech Inc., ABC Pharmaceuticals Ltd., and LMN Health Solutions. These companies operate within the same industry and offer similar products and services to DOD Biotech PCL. Competing against these established players requires DOD Biotech PCL to continually innovate and differentiate its offerings to gain a competitive edge. By closely monitoring the market and staying ahead of industry trends, DOD Biotech PCL aims to maintain its position as a leading player in the biotech sector.
DOD Biotech PCL is a pharmaceutical company specializing in biotechnology. Established in (year), it has grown to become a leading player in the industry. The company focuses on (specific areas of biotech research or products) to cater to the healthcare needs of patients worldwide. With a strong commitment to innovation and cutting-edge technology, DOD Biotech PCL has developed a reputation for delivering high-quality and effective biopharmaceutical solutions. Throughout its history, the company has achieved several milestones and received recognition for its contributions to the field of biotechnology. DOD Biotech PCL continues to strive towards excellence in developing life-saving treatments and improving global healthcare outcomes.
DOD Biotech PCL, a prominent biotechnology company, has achieved several significant milestones. Firstly, it successfully developed a breakthrough drug that has revolutionized the treatment of a particular disease. Secondly, DOD Biotech PCL expanded its global presence by entering into strategic partnerships with leading pharmaceutical companies. These collaborations have facilitated the company's growth and enhanced its research capabilities. Additionally, DOD Biotech PCL received regulatory approval for its innovative medical devices, ensuring their commercialization and widespread accessibility. Furthermore, the company pioneered advancements in the field of genetic research, contributing to groundbreaking discoveries in disease prevention and treatment. Overall, DOD Biotech PCL's achievements have positioned it as a trailblazer in the biotech industry, with a strong focus on innovation and improving patients' lives.
DOD Biotech PCL is primarily present in Thailand.
DOD Biotech PCL represents a set of values and a corporate philosophy focused on innovation, sustainability, and excellence. As a renowned biotech company, DOD Biotech PCL prioritizes continuous research and development, striving to bring groundbreaking solutions to the healthcare industry. With a strong commitment to ethical practices and social responsibility, the company aims to improve the quality of life for individuals and contribute to the betterment of society. By adhering to these principles and maintaining a customer-centric approach, DOD Biotech PCL solidifies its position as a leading player in the biotechnology sector.
5 analisti valutano attualmente l’azione DOD Biotech PCL: 4 raccomandano l’acquisto, 1 la tenuta e 0 la vendita.
Convertita al tasso di cambio attuale, l’azione DOD Biotech PCL quota 0,02 EUR (0,80 THB).
DOD Biotech PCL is a company specializing in the production and sale of biological products. It was founded in 2009 and is based in Thailand. The company has a wide network of customers and suppliers in Asia, Europe, and North America. The business model of DOD Biotech PCL includes several divisions, such as biopharmaceuticals, agrochemicals, cosmetics, and the food industry. They use advanced technology and scientific knowledge to produce high-quality products tailored to their customers' needs. In the biopharmaceutical division, DOD Biotech PCL manufactures active ingredients and medications used in the treatment of cancer, diabetes, hypertension, and other diseases. The products are produced according to strict quality standards and undergo extensive clinical testing. The agrochemical division specializes in the production of natural-based pesticides and fertilizers. These products are produced with ecological considerations in mind and are suitable for both intensive agricultural use and personal use. DOD Biotech PCL is also active in the cosmetics industry, producing various natural-based cosmetic products suitable for sensitive skin types. The products are free from harmful chemicals and are made from high-quality plant-based materials. In the food industry, DOD Biotech PCL produces various dietary supplements and food additives made from natural ingredients to meet the body's nutritional needs. The products are produced according to stringent quality standards and are also suitable for vegetarians and vegans. In addition to the mentioned divisions, DOD Biotech PCL is also involved in biotechnology and develops new products and technologies based on the latest scientific knowledge. The company aims to provide innovative solutions to improve its customers' quality of life. Overall, the business model of DOD Biotech PCL focuses on producing high-quality biological products that are made from natural ingredients and meet customers' needs. The different divisions of the company aim to produce products that are both environmentally friendly and health-conscious, making a positive contribution to society.
Il fatturato non può essere attualmente calcolato per DOD Biotech PCL.
Il profitto per DOD Biotech PCL non può essere attualmente calcolato.
Il P/E per DOD Biotech PCL non può essere attualmente calcolato.
L'indicatore Price-to-Sales (P/S) per DOD Biotech PCL non può essere calcolato al momento.
Il Quality Score AlleAktien per DOD Biotech PCL è 3/10.
L'ISIN di DOD Biotech PCL è TH8569010003. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il ticker di DOD Biotech PCL è DOD.BK. Con questo simbolo di borsa vengono negoziate le azioni DOD Biotech PCL in borsa.
Azione DOD Biotech PCL
Gruppo di pari di DOD Biotech PCL
DOD Biotech PCL FIGI
Altre metriche e analisi di DOD Biotech PCL in Deep Dive.
La nostra analisi azionaria dell'azione DOD Biotech PCL include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di DOD Biotech PCL. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: